CorMedix, Inc. (NASDAQ:CRMD) Q3 2019 Earnings Conference Call November 14, 2019 4:30 PM ET CompanyParticipants Dan Ferry - MD, LifeSci Advisors Khoso Baluch - CEO Phoebe Mounts - EVP & General Counsel Jack Armstrong - EVP, Technical Operations Bob Cook - CFO Conference Call Participants John Ledon - Novel Consulting Group Operator Greetings. Welcome to CorMedix's Inc. Third Quarter 2019 Earnings Conference Call. [Operator Instructions] Please note, this conference is being recorded. I would now like to turn ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Delaware 20-5894890 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.001 par value CRMD NYSE American LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSU ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | HarnessingTaurolidine | | | | | | | | | | Technology Leading Development of Novel Anti-Infective Products in the Era of Increasing Bacterial Resistance Cantor Global Healthc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-34673 CORMEDIX INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894890 (State or Other Jur ...

CorMedix, Inc. (NASDAQ:CRMD) Q2 2019 Results Conference Call August 13, 2019 4:30 PM ET Company Participants Dan Ferry - MD, LifeSci Advisors Khoso Baluch - CEO Bob Cook - CFO Phoebe Mounts - EVP and General Counsel Jack Armstrong - EVP, Technical Operations Conference Call Participants Ram Selvaraju - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to your CorMedix Second Quarter 2019 Earnings Conference Call. All lines have been place on a listen-only mode, and the floor will be open ...

CorMedix, Inc. (NASDAQ:CRMD) Q1 2019 Results Earnings Conference Call May 13, 2019 4:30 PM ET Company Participants Dan Ferry - IR-LifeSci Advisors Khoso Baluch - CEO Bob Cook - CFO Phoebe Mounts - EVP and General Counsel Paul Chew - Chief Medical Officer Conference Call Participants Operator Greetings. Welcome to CorMedix's First Quarter 2019 Earnings Conference Call. [Operator Instructions] Please note this conference is being recorded. I would now like to turn the conference over to your host Mr. Dan Fer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-34673 CORMEDIX INC. (Exact Name of Registrant as Specified in Its Charter) | --- | --- | |----------------------- ...

CorMedix Inc. (NASDAQ:CRMD) Q4 2018 Results Conference Call March 14, 2019 4:30 PM ET Company Participants Daniel Ferry - IR LifeSci Advisors Khoso Baluch - CEO Bob Cook - CFO Liz Masson - EVP and Head of Clinical Operations Paul Chew - Chief Medical Officer Conference Call Participants Ram Selvaraju - H.C. Wainwright Jerry Isaacson - ROTH Capital Operator Greetings, and welcome to CorMedix Fourth Quarter 2018 Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to ______________________ Commission file number: 001-34673 CORMEDIX INC. (Exact name of Registrant as Specified in Its Charter) Delaware 2 ...